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Serum Metabolites as Diagnostic 
Biomarkers for Cholangiocarcinoma, 
Hepatocellular Carcinoma, and Primary 
Sclerosing Cholangitis
Jesus M. Banales,1,2,3 Mercedes Iñarrairaegui,2,4 Ander Arbelaiz,1 Piotr Milkiewicz,5 Jordi Muntané,2,6 Luis Muñoz-Bellvis,7  
Adelaida La Casta,1 Luis M. Gonzalez,7 Enara Arretxe,8 Cristina Alonso,8 Ibon Martínez-Arranz,8 Ainhoa Lapitz,1  
Alvaro Santos-Laso,1 Matias A. Avila,2,9 Maria L. Martínez-Chantar,2,10 Luis Bujanda,1,2 Jose J.G. Marin,2,11 Bruno Sangro,2,4,* and 
Rocio I.R. Macias 2,11,*
Early and differential diagnosis of intrahepatic cholangiocarcinoma (iCCA) and hepatocellular carcinoma (HCC) by 
noninvasive methods represents a current clinical challenge. The analysis of low-molecular-weight metabolites by 
new high-throughput techniques is a strategy for identifying biomarkers. Here, we have investigated whether serum 
metabolome can provide useful biomarkers in the diagnosis of iCCA and HCC and could discriminate iCCA from 
HCC. Because primary sclerosing cholangitis (PSC) is a risk factor for CCA, serum metabolic profiles of PSC and 
CCA have also been compared. The analysis of the levels of lipids and amino acids in the serum of patients with 
iCCA, HCC, and PSC and healthy individuals (n = 20/group) showed differential profiles. Several metabolites pre-
sented high diagnostic value for iCCA versus control, HCC versus control, and PSC versus control, with areas 
under the receiver operating characteristic curve (AUC) greater than those found in serum for the nonspecific tumor 
markers carbohydrate antigen 19-9 (CA 19-9) and alpha-fetoprotein (AFP), commonly used to help in the diagnosis 
of iCCA and HCC, respectively. The development of an algorithm combining glycine, aspartic acid, SM(42:3), and 
SM(43:2) permitted to accurately differentiate in the diagnosis of both types of tumors (biopsy-proven). The pro-
posed model yielded 0.890 AUC, 75% sensitivity, and 90% specificity. Another algorithm by combination of 
PC(34:3) and histidine accurately permitted to differentiate PSC from iCCA, with an AUC of 0.990, 100% sensitiv-
ity, and 70% specificity. These results were validated in independent cohorts of 14-15 patients per group and com-
pared with profiles found in patients with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Conclusion: 
Specific changes in serum concentrations of certain metabolites are useful to differentiate iCCA from HCC or PSC, 
and could help in the early diagnosis of these diseases. (Hepatology 2019;70:547-562).
Cholangiocarcinoma (CCA) includes a hetero-geneous group of biliary cancers with a dis-mal prognosis.(1) Their incidence is increasing 
worldwide, representing a significant health problem. 
The bad outcome of CCAs is due to their late diagno-
sis and refractory nature. According to the anatomical 
location, CCAs are classified as intrahepatic (iCCA), 
perihilar, or distal. In particular, iCCA accounts for 
10%-15% of all CCAs,(2) and, as opposed to other 
primary liver cancers, its mortality rate has risen in 
most Western countries over the past decades.(3) 
iCCA is generally asymptomatic in early stages and 
is commonly diagnosed in advanced phases, when 
symptoms arise and the disease is found disseminated, 
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which limits current potentially curative options based 
on surgery or liver transplantation.(4,5) Therefore, only 
25%-30% of patients with iCCA are eligible for sur-
gery at the time of diagnosis. A combination of radio-
logical, biochemical, and histological approaches is 
required to confirm the iCCA diagnosis. Moreover, 
histological analyses of tumor biopsies are required to 
differentially diagnose iCCA from the most common 
type of primary liver cancer, hepatocellular carcinoma 
(HCC), which is fundamental for providing adequate 
first-line treatments as indicated by international 
guidelines.(6) However, tumor biopsy is not indicated 
in the majority of cases because of the advanced dis-
ease stage and concomitant risks. The etiology of most 
iCCAs is unknown, although chronic cholestatic liver 
diseases, such as primary sclerosing cholangitis (PSC), 
are risk factors.(5) Currently, early diagnosis of CCA 
in patients with PSC by noninvasive methods is chal-
lenging and highly compromises patient outcome.(7)
Therefore, there is an urgent need for accurate 
noninvasive biomarkers for the early and differential 
diagnosis of iCCA and HCC. Cancer cells are highly 
metabolically active,(8) which is both cause and conse-
quence of their pathogenesis, but this may also repre-
sent an opportunity for diagnosis and treatment. The 
analysis of the metabolome in body fluids is emerg-
ing as a diagnostic strategy that could be associated 
with the progression of the disease.(9) In this con-
text, the aim of the present study was to determine 
serum metabolomic profiles in the search of accurate 
Supported by CIBERehd (EHD15PI05), AECC Scientific Foundation (2017/2020), “Fondo de Investigaciones Sanitarias” (Carlos III Health 
Institute: PI15/01132 and PI18/01075 to J.M.B., PI16/00598 to J.J.G.M., PI16/01845 to B.S., PI16/01126 to M.A.A., PI16/00090 to J.M.), 
Spanish Ministry of Economy, Industry and Competitiveness (SAF2016-75197-R to R.I.R.M., SAF2017-87301-R to M.L.M.-C.), Miguel 
Servet Programme (CON14/00129 to J.M.B.), “Diputación Foral de Gipuzkoa” (DFG15/010, DFG16/004 to J.M.B.), “Basque Foundation 
for Innovation and Health Research: EiTB Maratoia” (BIO15/CA/016/BD to J.M.B., BIO15/CA/016/BD to M.L.M.-C.), Basque Country 
Department of Health (2013111173 to L.B., 2017111010 to J.M.B., 2013111114 to M.L.M.-C.), the Andalusian Government (“Consejería 
de Economía, Innovación, Ciencia y Empleo”: CTS-6264 and “Consejería de Salud”: PI-0198-2016 to J.M.), Junta de Castilla y León, Spain 
(SA063P17 to J.J.G.M.), European Comission Horizon 2020 project (SEP-210503876; ESCALON to J.M.B.), and Proyecto Hepacare, Fundación 
La Caixa (to M.A.A.).
© 2018 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases. This is 
an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution 
in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
View this article online at wileyonlinelibrary.com.
DOI 10.1002/hep.30319
Potential conflict of interest: Drs. Martínez-Arranz, Alonso, and Arretxe are employed by One Way Liver, S.L. Dr. Banales is member of the 
scientific advisory board of OWL Metabolomics.
aRtICle INFoRMatIoN:
From the 1 Department of Liver and Gastrointestinal Diseases,  Biodonostia Research Institute, Donostia University Hospital, 
University of the Basque Country (UPV/EHU), San Sebastian, Spain; 2 National Institute for the Study of Liver and 
Gastrointestinal Diseases (CIBERehd, Carlos III Health Institute), Madrid, Spain; 3 IKERBASQUE,  Basque Foundation for 
Science, Bilbao, Spain; 4 Liver Unit,  Clínica Universidad de Navarra-IDISNA, Pamplona, Spain; 5 Liver and Internal Medicine 
Unit, Department of General, Transplant and Liver Surgery,  Medical University of Warsaw, Warsaw, Poland; 6 Department of 
General Surgery “Virgen del Rocío” University Hospital/IBiS/CSIC/University of Seville, Seville, Spain; 7 Service of General and 
Gastrointestinal Surgery,  University Hospital of Salamanca, Biomedical Research Institute of Salamanca (IBSAL), CIBERONC, 
Salamanca, Spain; 8 OWL Metabolomics,  Bizkaia Technology Park, Derio, Spain; 9 Program of Hepatology, Center for Applied 
Medical Research (CIMA),  University of Navarra-IDISNA, Pamplona, Spain; 10 CIC bioGUNE,  Bizkaia Technology Park, Derio, 
Spain; 11 Experimental Hepatology and Drug Targeting (HEVEFARM),  University of Salamanca, Biomedical Research Institute 
of Salamanca (IBSAL), Salamanca, Spain.
aDDReSS CoRReSpoNDeNCe aND RepRINt ReQUeStS to: 
Rocio I.R. Macias, Ph.D.
Department of Physiology and Pharmacology
Campus Miguel de Unamuno E.D. B-17
E-37007, Salamanca, Spain
E-mail: rociorm@usal.es
Tel: +1-34-666596621
or
Jesus M. Banales, Ph.D.
Department of Liver and Gastrointestinal Diseases, Biodonostia 
Health Research Institute – Donostia University Hospital
Paseo del Dr. Begiristain s/n
E-20014, San Sebastian, Spain
E-mail: jesus.banales@biodonostia.org
Tel: +1-34-943006067
Hepatology, Vol. 70, No. 2, 2019 BANALES, ET AL.
549
diagnostic biomarkers that could be used to distin-
guish iCCA from HCC or PSC, and also for the early 
diagnosis of these diseases.
Material and Methods
StUDy popUlatIoN aND 
elIgIBIlIty
Serum samples from patients with iCCA, HCC, 
and PSC and healthy individuals (n = 20/group in the 
“discovery cohort” and n = 14-15/group in the “vali-
dation cohort”) and from patients with nonalcoholic 
fatty liver disease (NAFLD) and nonalcoholic steato-
hepatitis (NASH; n = 20/group) were obtained from 
the Donostia University Hospital (San Sebastian, 
Spain), the Biobank of “Clínica Universidad de 
Navarra” (Pamplona, Spain), the National DNA 
Bank-Carlos III of University of Salamanca 
(Salamanca, Spain), the Biobank of the University 
Hospital “Vírgen del Rocío-Instituto de Biomedicina 
de Sevilla” (Seville, Spain), and the Medical University 
of Warsaw (Warsaw, Poland). The research protocol 
was approved by the Ethics Committee for Clinical 
Research of each supporting institution, and all sub-
jects provided written consent for their samples to be 
used for biomedical research.
Inclusion criteria for patients with iCCA and HCC 
included the following: 1) diagnosis confirmed by his-
topathology; 2) availability of serum samples obtained 
just after diagnosis and before patients had received 
any type of treatment; and 3) availability of complete 
demographic and clinical information. Exclusion 
criteria were as follows: 1) “mixed” tumors, as diag-
nosed by histopathology; 2) no definite diagnosis of 
iCCA or HCC; and 3) the presence of other types 
of malignancy. The histologic diagnoses of iCCA or 
HCC were established by expert liver pathologists at 
each participating hospital, and tumors were classified 
according to the 7th edition of the American Joint 
Committee on Cancer Staging Manual(10) and the 
Barcelona Clinic Liver Cancer (BCLC) staging sys-
tem,(11) respectively.
Patients with PSC were diagnosed by the presence of 
bile duct alterations (multifocal strictures and segmen-
tal dilatations) by cholangiography and by the exclusion 
of secondary sclerosing cholangitis causes, following the 
guidelines of the European Association for the Study of 
the Liver.(12) All patients with PSC were treated with 
ursodeoxycholic acid (UDCA).
Inclusion criteria for patients with NAFLD or 
NASH were as follows: 1) diagnosis by histopathol-
ogy NAFLD Activity Score (NAS score); 2) absence 
of acute or chronic disease except obesity or type 2 
diabetes; and 3) alcohol consumption <20 g/day for 
women and <30 g/day for men. Exclusion criteria were 
other causes of liver disease, such as viral hepatitis.
For all subjects, blood was obtained under fasting 
conditions and serum was collected and stored at 
-80°C until analysis. Patient information and labora-
tory test values were collected retrospectively from the 
patients’ records.
MetaBoloMIC aNalySeS
The semi-quantification of the serum metabolic 
profiles was performed, as previously described.(13) 
Briefly, two ultra-high-performance liquid chroma-
tography (UHPLC)-time-of-flight-mass spectrometry 
(MS)–based platforms analyzing methanol and chlo-
roform/methanol serum extracts were combined with 
the amino acids measurement by a UHPLC-single-
quadrupole-MS–based analysis. Identified ion features 
in the methanol extract platform included acyl carni-
tines, bile acids, free sphingoid bases, monoacylglycer-
ophospholipids, monoetherglycerophospholipids, fatty 
acids, and oxidized fatty acids. The coverage of the chlo-
roform/methanol extract included glycerolipids, diacyl-
glycerophospholipids, acyl-ether-glycerophospholipids, 
cholesteryl esters, and sphingolipids. Lipid nomencla-
ture and classification follows the LIPID MAPS con-
vention (www.lipidmaps.org). Metabolite extraction 
procedures for each platform, as well as the chromato-
graphic separation conditions and mass spectrometric 
detection conditions, have been previously described in 
detail.(13) Metabolomics data were preprocessed using 
the TargetLynx application manager for MassLynx 4.1 
(Waters Corp., Milford, MA). Intra- and inter-batch 
normalization was performed by inclusion of multiple 
internal standards and pool calibration response correc-
tion, following a previously described procedure.(14)
StatIStICal aNalySIS
Data are shown as mean ± SD. Differences between 
groups were determined using the Student t-test or 
the Bonferroni method of multiple range test, where 
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appropriate. Volcano plot analysis was performed as an 
effective and easy-to-understand graph that summa-
rizes fold-change and significance. It is a scatterplot 
of the negative log10-transformed P values from the 
t test against the log2 fold-change. Multivariate prin-
cipal component analysis (PCA) and orthogonal par-
tial least squares (OPLS) modeling were performed 
with the software SIMCA 14.1 (Umetrics, Malmo, 
Sweden). All calculations were performed using the 
statistical software package R v.3.4.0 (R Development 
Core Team, 2017; https://cran.r-project.org).
To find statistical models to differentiate iCCA ver-
sus HCC or PSC, a generalized linear model (GLM) 
was used to differentiate iCCA versus HCC or PSC, 
and leave-one-out cross validation (LOOCV) was 
performed to confirm the model. Box-Cox transfor-
mations were applied to the biomarker metabolite 
levels for correcting non-normally distributed data 
and used to calculate the classification algorithm. The 
diagnostic accuracy of the model to identify patients 
in each comparison was assessed using the area under 
the receiver operating characteristic curve (AUC).
Results
CHaRaCteRIStICS oF tHe 
StUDy popUlatIoN
The demographic and clinical features of par-
ticipants of the discovery cohort are summarized 
in Table 1A. No differences between the metabolic 
profiles of the samples due to the hospital of origin 
were found, as demonstrates the unsupervised PCA 
in Supporting Fig. 1A. Despite differences in mean 
age of patients among groups, and in gender in the 
control group compared with the other groups, no 
differences between serum metabolic profiles of the 
samples due to gender or age were found, as shown in 
the unsupervised PCAs in Supporting Figs. S1B, S1C, 
respectively. Moreover, no difference among patients 
due to the presence or absence of liver cirrhosis was 
found (Supporting Fig. S1D). PCA analysis showed 
that patients with iCCA clustered together irrespec-
tive of the stage (Supporting Fig. S1E), whereas the 
effect of tumor stage could not be analyzed in patients 
with HCC because most of them presented a BCLCA 
stage (Supporting Fig. S1F). A random distribution 
of the samples of patients and controls was observed 
(Supporting Fig. S1G). Statistical comparisons of the 
liver biochemical data (Table 1A) revealed higher lev-
els of transaminases, alkaline phosphatase, and gam-
ma-glutamyl transpeptidase in the serum of patients 
with PSC compared with healthy controls and, in 
some cases, also compared with patients with liver 
cancers. An important variability in the levels of non-
specific tumor biomarkers CA 19-9 and α-fetoprotein 
(AFP) was found in the serum of patients with iCCA 
and HCC, respectively. The demographic and clini-
cal characteristics of patients of the validation cohort 
(Table 1B) were, in general, quite similar to those 
described for the discovery cohort. Supporting Fig. 1H 
shows that patients clustered together in both discov-
ery and validation cohorts.
MetaBoloMIC pRoFIlINg 
IN SeRUM FRoM patIeNtS 
WItH ICCa, HCC, aND pSC aND 
HealtHy INDIVIDUalS
A total of 424 metabolites in serum samples were 
identified in both cohorts (discovery and validation) 
and included in the subsequent univariate and mul-
tivariate data analyses. Notably, one analysis comple-
ments the other, and although their results do not 
always coincide, the use of both methods offers import-
ant advantages in data mining.(15) Supporting Fig. S2 
shows the heatmaps representing fold-changes and P 
values generated for the different two-group compar-
isons in the discovery cohort, in the validation cohort, 
and considering all samples together. Changes in the 
levels of several compounds belonging to different 
families of metabolites, such as amino acids, saturated, 
monounsaturated and polyunsaturated fatty acids, 
diglycerides, triglycerides, cholesteryl esters, bile acids, 
steroids, lysophosphatidylethanolamines, lysophospha-
tidylcholines, phosphatidylinositols, ceramides, sphin-
gomyelins, and monohexosylceramides, were found in 
all comparisons. The most interesting changes for each 
comparison are described in detail below.
CoMpaRatIVe SeRUM 
MetaBoloMIC CoNteNt IN 
tHe DISCoVeRy CoHoRt
The unsupervised PCA model showed no sepa-
ration in the serum metabolomic profiles between 
iCCA and control subjects (Supporting Fig. S3A), 
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and the supervised OPLS model showed a low 
predictive ability (Supporting Fig. S3B), because 
the Q2X value was low (0.258). However, as 
shown in the volcano plot generated for this com-
parison (Fig. 1A), a total of 52 metabolites were 
altered in serum from patients with iCCA, where 
taBle 1a. Demographic and Clinical Characteristics of the Study population
Variable Control (n = 20) iCCA (n = 20) HCC (n = 20) PSC (n = 20)
Age, mean ± SD 54.6 ± 15.5 68.4 ± 9.8* 58.8 ± 7.1* 33.6 ± 9.6*†
Age, range 25-72 46-81 49-71 19-54
Males, n (%) 8 (40) 12 (60) 19 (95) 16 (80)
Underlying disease, n (%)
Cirrhosis 0 (0) 5 (25) 19 (95) 8 (40)
Hepatitis B virus 0 (0) 0 (0) 1 (5) 0 (0)
Hepatitis C virus 0 (0) 2 (10) 13 (65) 0 (0)
Alcoholic NA 5 (25) 7 (35) NA
Diabetes 3 (15) 2 (10) 7 (35) NA
Ulcerative colitis 0 (0) 0 (0) 0 (0) 16 (80)
Number of nodules, n (%)
Single — 15 (75) 17 (85) —
Two — 2 (10) 2 (10) —
More than two — 2 (10) 1 (5) —
Unknown — 1 (5) 0 (0) —
Nodule size (cm), n (%)
<5 — 11 (55) 19 (95) —
5-10 — 4 (20) 1 (5) —
>10 — 2 (10) 0 (0) —
Unknown — 3 (15) 0 (0) —
Tumor stage, n (%)
BCLCA — — 18 (90) —
BCLCB — — 1 (5) —
BCLCC — — 1 (5) —
I — 9 (45) — —
II — 2 (10) — —
III — 3 (15) — —
IV — 6 (30) — —
Tumor grade, n (%)
Well differentiated — 5 (25) 7 (35) —
Moderately differentiated — 10 (50) 13 (65) —
Poorly differentiated — 1 (5) 0 (0) —
Unknown — 4 (20) 0 (0) —
Biochemistry, mean ± SD
ALT (IU/L) 27.4 ± 14.1 42.0 ± 40.2 50.5 ± 34.8 107 ± 89*†
AST (IU/L) 23.6 ± 8.2 51.8 ± 50.3 46.6 ± 23.8 97.1 ± 73.4*
GGT (IU/L) 31.0 ± 20.1 134 ± 117* 118 ± 84.7* 281 ± 311*
Alkaline phosphatase (IU/L) 68.8 ± 18.9 165 ± 101* 77.9 ± 25.4† 335 ± 256*
Total bilirubin (mg/dL) 0.7 ± 0.3 1.5 ± 2.9 0.9 ± 0.7 4.5 ± 10.5
CA 19-9 (IU/mL) 9.8 ± 7.4 1,746 ± 4,921 29.3 ± 28.6 51.9 ± 121
AFP (ng/mL) 2.8 ± 2.1 3.2 ± 2.4 117 ± 267 NA
*P < 0.05 compared with control.
†P < 0.05 compared with iCCA, by the Bonferroni method of multiple-range testing.
Abbreviations: AFP, alpha-fetoprotein; ALT; alanine aminotransferase, AST; aspartate aminotransferase, BCLC, Barcelona Clinic 
Liver Cancer; GGT, gamma-glutamyl transpeptidase; CA19-9, carbohydrate antigen 19-9; HCC, hepatocellular carcinoma; iCCA, 
intrahepatic cholangiocarcinoma; NA, not available; PSC, primary sclerosing cholangitis.
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phosphatidylcholines > amino acids ≈ sphingomy-
elins and sterols were the most abundant metabo-
lite families found to be altered (Fig. 1B). Fig. 1C 
shows the nine metabolites with the highest AUC, 
sensitivity, and specificity also found altered in the 
validation cohort. All of them presented higher val-
ues than CA 19-9, the unspecific tumor biomarker 
clinically used in the diagnosis of CCA.
taBle 1B. Demographic and Clinical Characteristics of the Validation Cohort
Variable Control (n = 15) iCCA (n = 15) HCC (n = 14) PSC (n = 15)
Age, mean ± SD 52.5 ± 9.9 70.7 ± 5.4* 62.1 ± 9.2 38.3 ± 8.2*†
Age, range 32-68 61-81 46-75 30-61
Males, n (%) 7 (46.7) 8 (53.3) 13 (92.9) 9 (60)
Underlying disease, n (%)
Cirrhosis 0 (0) 2 (13.3) 10 (71.4) 2 (13.3)
Hepatitis B virus 0 (0) 0 (0) 0 (0) 0 (0)
Hepatitis C virus 0 (0) 0 (0) 5 (35.7) 0 (0)
Alcoholic 0 (0) 6 (40) 9 (64.3) 0 (0)
Diabetes 0 (0) 5 (33.3) 4 (28.6) NA
Ulcerative colitis 0 (0) 0 (0) 0 (0) 12 (80)
Number of nodules, n (%)
Single — 11 (73.3) 8 (57.2) —
Two — 3 (20) 3 (21.4) —
More than two — 1 (6.7) 3 (21.4) —
Nodule size (cm), n (%)
<5 — 9 (60) 9 (64.3) —
5-10 — 5 (33.3) 3 (21.4) —
>10 — 1 (6.7) 2 (14.3) —
Tumor stage, n (%)
BCLCA — — 10 (71.4) —
BCLCB — — 2 (14.3) —
BCLCC — — 2 (14.3) —
I — 6 (40) — —
II — 3 (20) — —
III — 2 (13.3) — —
IV — 4 (26.7) — —
Tumor grade, n (%)
Well differentiated — 4 (26.7) 3 (21.4) —
Moderately differentiated — 3 (20) 9 (64.3) —
Poorly differentiated — 3 (20) 0 (0) —
Unknown — 5 (33.3) 2 (0) —
Biochemistry, mean ± SD
ALT (IU/L) 29.7 ± 12.6 36.3 ± 37.1 41.4 ± 16.0 92.5 ± 103.4*†
AST (IU/L) 18.8 ± 5.9 33.5 ± 13.5 60.4 ± 41.9 52.0 ± 40.0*
GGT (IU/L) 25.4 ± 19.0 293 ± 240 133 ± 65 268 ± 233*
Alkaline phosphatase (IU/L) 54.5 ± 14.5 203 ± 169 109 ± 39 238 ± 273*†
Total bilirubin (mg/dL) 0.6 ± 0.3 1.9 ± 4.2 1.3 ± 1.9 0.9 ± 0.5
CA 19-9 (IU/mL) 6.9 ± 7.6 535 ± 1,332 NA 24.1 ± 56.8
AFP (ng/mL) 2.4 ± 0.9 2.0 ± 0.9 250 ± 496 NA
*P < 0.05 compared with control.
†P < 0.05 compared with iCCA, by the Bonferroni method of multiple-range testing.
Abbreviations: AFP, alpha-fetoprotein; ALT; alanine aminotransferase, AST; aspartate aminotransferase, BCLC, Barcelona Clinic 
Liver Cancer; GGT, gamma-glutamyl transpeptidase; CA19-9, carbohydrate antigen 19-9; HCC, hepatocellular carcinoma; iCCA, 
intrahepatic cholangiocarcinoma; NA, not available; PSC, primary sclerosing cholangitis.
Hepatology, Vol. 70, No. 2, 2019 BANALES, ET AL.
553
The unsupervised PCA model generated for the 
comparison of HCC versus control revealed a poten-
tial separation between groups (Supporting Fig. 
S3C), and the supervised OPLS model separated 
both groups with moderate predictive ability (Q2X = 
0.499) (Supporting Fig. S3D). The volcano plot (Fig. 
2A) showed that 104 metabolites were altered in the 
serum from patients with HCC, mainly phosphati-
dylcholines ≈ sphingomyelins ≈ triglycerides > amino 
acids, cholesteryl esters > lysophosphatidylcholines 
(Fig. 2B). The 13 metabolites with the highest AUC, 
sensitivity, and specificity in this comparison, and sim-
ilarly found altered in the validation cohort, are shown 
in Fig. 2C. Most of them showed higher values than 
the biomarker AFP.
The unsupervised PCA model performed includ-
ing patients with HCC and iCCA (Supporting Fig. 
S3E) showed no clear separation of samples, and the 
supervised OPLS discriminant analysis (Supporting 
Fig. S3F) showed a negative predictive ability 
FIg. 1. Comparative serum metabolomic profiles of patients with iCCA and controls in the discovery cohort. (A) Volcano plot 
(−log10[P value] and log2[fold-change]) of the serum metabolic ion features of patients with iCCA compared with controls. (B) Percentage 
of metabolite classes significantly different in the serum of patients with iCCA compared with healthy individuals. (C) Diagnostic 
capacity of the nine selected metabolites also similarly found altered in the validation cohort. Abbreviations: AA, amino acids; AC, 
acylcarnitines; AUC, area under the receiver operating characteristic curve; BA, bile acids; Cer, ceramides; ChoE, cholesteryl esters; 
CMH, monohexosylceramides; DG, diglycerides; DHEAS, dehydroepiandrosterone sulfate; FC, fold-change; FSB, free sphingoid bases; 
GCA, glychocolic acid; GCDCA, glychochenodeoxycholic acid; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; 
LPI, lysophosphatidylinositols; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; oxFA, oxidized fatty acids; PC, 
phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; PUFA, polyunsaturated fatty acids; SEN, sensitivity; 
SFA, saturated fatty acids; SM, sphingomyelins; SPE, specificity; ST, steroids; TG, triglycerides.
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(Q2X = −0.013). In addition, a total of 58 metabo-
lites were different upon comparing the serum of 
patients with both types of liver cancer (Fig. 3A). 
Different levels of amino acids > sphingomyelins ≈ 
triglycerides > diglycerides and other metabolite spe-
cies were found when comparing HCC versus iCCA 
(Fig. 3B); more precisely, this included seven amino 
acids, three sphingomyelins, and eight glycerolipids. 
Fig. 3C shows six metabolites with the highest val-
ues of AUC, sensitivity, and specificity for this com-
parison, and that were also found similarly altered in 
the validation cohort. The six independent metabo-
lites showed higher AUC diagnostic values than CA 
19-9. However, the ability of AFP to discriminate 
iCCA from HCC was higher than that of CA 19-9, 
and the AUC value was also a little higher than the 
values of some of the aforementioned metabolites 
analyzed independently. Of note, one of the selected 
candidate metabolites for the differential diagnosis of 
iCCA versus HCC (i.e., hypotaurine) improved its 
diagnostic values when comparing early-stage iCCA 
(I-II) versus HCC (Fig. 3D), and also showed higher 
FIg. 2. Comparative serum metabolomic profiles of patients with HCC and controls in the discovery cohort. (A) Volcano plot 
(−log10[P value] and log2[fold-change]) of the serum metabolic ion features of patients with HCC compared with controls. (B) 
Percentage of metabolite classes significantly different in the serum of patients with HCC compared with healthy individuals. (C) 
Diagnostic capacity of the 13 selected metabolites also similarly found altered in the validation cohort. Abbreviations: AA, amino acids; 
AC, acylcarnitines; AUC, area under the receiver operating characteristic curve; BA, bile acids; Cer, ceramides; ChoE, cholesteryl 
esters; CMH, monohexosylceramides; DG, diglycerides; FC, fold-change; FSB, free sphingoid bases; LPC, lysophosphatidylcholines; 
LPE, lysophosphatidylethanolamines; LPI, lysophosphatidylinositols; MUFA, monounsaturated fatty acids; NAE, N-acyl 
ethanolamines; oxFA, oxidized fatty acids; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; 
PUFA, polyunsaturated fatty acids; SEN, sensitivity; SFA, saturated fatty acids; SM, sphingomyelins; SPE, specificity; ST, steroids; 
TG, triglycerides.
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diagnostic values than CA 19-9 (AUC [95% confi-
dence interval], 0.586 [0.385-0.765]) and similar to 
AFP (AUC [95% confidence interval], 0.809 [0.673-
0.942]) in this comparison.
As a secondary aim, we investigated the serum met-
abolic profile of patients with PSC, which allowed 
PSC to be distinguished from iCCA. The unsuper-
vised PCA model revealed a degree of separation 
between PSC and control individuals (Supporting 
Fig. S3G), whose significance increased following a 
supervised OPLS discriminant analysis to potentiate 
the differences between groups (Supporting Fig. S3H; 
model predictive ability Q2X = 0.565). The volcano 
plot generated for this comparison (Fig. 4A) showed 
that patients with PSC had higher levels of bile acids, 
phosphatidylethanolamines, phosphatidyl- and lyso-
phosphatidyl-cholines, and lysophosphatidylinositols, 
together with a decrease in some species of fatty acids, 
sphingomyelins, and triglycerides, where phosphati-
dylcholines ≈ lysophosphatidylcholines > triglycerides 
FIg. 3. Comparative serum metabolomic profiles of patients with HCC and iCCA in the discovery cohort. (A) Volcano plot 
(−log10[P value] and log2[fold-change]) of the serum metabolic ion features of patients with iCCA compared with HCC. (B) Percentage 
of metabolite classes significantly different in the serum of patients with HCC versus iCCA. (C) Diagnostic capacity of the six selected 
metabolites also similarly found altered in the validation cohort. Abbreviations: AA, amino acids; AC, acylcarnitines; AUC, area under 
the receiver operating characteristic curve; BA, bile acids; Cer, ceramides; ChoE, cholesteryl esters; CMH, monohexosylceramides; 
DG, diglycerides; FC, fold-change; FSB, free sphingoid bases; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; 
LPI, lysophosphatidylinositols; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; oxFA, oxidized fatty acids; PC, 
phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; PUFA, polyunsaturated fatty acids; SEN, sensitivity; 
SFA, saturated fatty acids; SM, sphingomyelins; SPE, specificity; ST, steroids; TG, triglycerides.
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> amino acid were the most abundant species altered 
in PSC (Fig. 4B). Also, 151 metabolites were found 
to be altered in the serum of these patients. Fig. 4C 
depicts the 24 metabolites with the highest AUC, sen-
sitivity, and specificity in this comparison, which were 
also found similarly altered in the validation cohort. 
Because patients with PSC had received treatment with 
UDCA, levels of conjugated UDCA were higher in 
patients with PSC as compared with healthy controls.
Finally, the unsupervised PCA performed with 
iCCA and PSC samples did not show a clear 
separation between these groups (Supporting Fig. 
S3I), but a potential separation between both groups 
was obtained when the supervised OPLS model 
was generated (Supporting Fig. S3J), with a mod-
erate predictive ability (Q2X = 0.554). The volcano 
plot generated for this comparison (Fig. 5A) showed 
102 metabolites altered in the serum of patients with 
iCCA versus PSC, mainly phosphatidylcholine and 
lysophosphatidylcholine species (Fig. 5B), which were 
lower in iCCA samples. Fig. 5C shows the 12 metab-
olites with the highest values of AUC, sensitivity, and 
FIg. 4. Comparative serum metabolomic profiles of patients with PSC and controls in the discovery cohort. (A) Volcano plot 
(−log10[P value] and log2[fold-change]) of the serum metabolic ion features of patients with PSC compared with controls. (B) Percentage 
of metabolite classes significantly different in the serum of patients with PSC compared with healthy individuals. (C) Diagnostic 
capacity of the 24 selected metabolites also similarly found altered in the validation cohort. Abbreviations: AA, amino acids; AC, 
acylcarnitines; AUC, area under the receiver operating characteristic curve; BA, bile acids; Cer, ceramides; ChoE, cholesteryl esters; 
CMH, monohexosylceramides; DG, diglycerides; FC, fold-change; FSB, free sphingoid bases; LPC, lysophosphatidylcholines; LPE, 
lysophosphatidylethanolamines; LPI, lysophosphatidylinositols; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; 
oxFA, oxidized fatty acids; PC, phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; PUFA, 
polyunsaturated fatty acids; SEN, sensitivity; SFA, saturated fatty acids; SM, sphingomyelins; SPE, specificity; ST, steroids; TG, 
triglycerides.
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specificity in both the discovery and also the valida-
tion cohort. All of them presented better diagnostic 
values than CA 19-9, and most of them improved 
their differential diagnosis values when comparing 
early-stage iCCA (I-II) versus PSC (Fig. 5D).
ValIDatIoN oF tHe 
BIoMaRKeRS aCCURaCy
The results obtained with the selected metab-
olites in the discovery cohort were confirmed in 
an independent validation cohort, as shown in 
Supporting Fig. S4, S5. Diagnostic models were built 
through GLM. An algorithm by combining glycine, 
aspartic acid, SM(42:3), and SM(43:2) permitted to 
differentiate both types of tumors with an AUC of 
0.890, 75% sensitivity, and 90% specificity (Fig. 6A). 
Fig. 6B shows the box plot diagram of the selected 
combination of metabolite biomarkers in the serum of 
patients and controls in the two independent cohorts. 
In the validation study, we also included groups of 
patients with NAFLD or NASH to confirm the 
FIg. 5. Comparative serum metabolomic profiles of patients with iCCA and PSC in the discovery cohort. (A) Volcano plot 
(−log10[P value] and log2[fold-change]) of the serum metabolic ion features of patients with iCCA compared with PSC. (B) Percentage 
of metabolite classes significantly different in the serum of patients with iCCA as compared with PSC. (C) Diagnostic capacity of the 12 
selected metabolites also similarly found altered in the validation cohort. Abbreviations: AA, amino acids; AC, acylcarnitines; AUC, area 
under the receiver operating characteristic curve; BA, bile acids; Cer, ceramides; ChoE, cholesteryl esters; CMH, monohexosylceramides; 
DG, diglycerides; FC, fold-change; FSB, free sphingoid bases; LPC, lysophosphatidylcholines; LPE, lysophosphatidylethanolamines; 
LPI, lysophosphatidylinositols; MUFA, monounsaturated fatty acids; NAE, N-acyl ethanolamines; oxFA, oxidized fatty acids; PC, 
phosphatidylcholines; PE, phosphatidylethanolamines; PI, phosphatidylinositols; PUFA, polyunsaturated fatty acids; SEN, sensitivity; 
SFA, saturated fatty acids; SM, sphingomyelins; SPE, specificity; ST, steroids; TG, triglycerides.
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accuracy (sensitivity and specificity) and usefulness of 
the selected metabolites. Fig. 6C shows the results in 
the discovery and validation cohorts of six additional 
different diagnostic models by combining metabo-
lites that permitted to differentiate iCCA and HCC. 
High values of AUC, sensitivity, and specificity were 
FIg. 6. Diagnostic prediction capacity of the selected metabolites in iCCA versus HCC, and iCCA versus PSC in discovery and 
validation cohorts. (A,B) Combination of aspartic acid, glycine, SM(42:3), and SM(43:2) in serum iCCA versus HCC. (C) Values 
of AUC, sensitivity, and specificity of other algorithms to differentiate iCCA versus HCC. (D,E) Combination of histidine and 
PC(34:3) in serum iCCA versus PSC (0.990 AUC, 100% sensitivity, 70% specificity, 76.9% positive predictive value, and 100% 
negative predictive value). Linear discriminant (A,C,D) analysis was carried out through LOOCV. (B,E) Box plot diagrams for each 
combination, respectively. Abbreviations: AUC, area under the receiver operating characteristic curve; N, number of metabolites in the 
algorithm; SEN, sensitivity; SPE, specificity. The asterisks indicate combination of metabolites.
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obtained, especially with the model including six 
metabolites, and all of them presented better values 
than AFP and CA 19-9.
Moreover, an algorithm consisting of PC(34:3) and 
histidine accurately permitted to differentiate between 
PSC and iCCA in the discovery cohort with an AUC 
of 0.990, 100% sensitivity, 70% specificity, and 85% 
accuracy, which was successfully confirmed in the vali-
dation cohort (Fig. 6D). Fig. 6E shows the box plot dia-
gram of the combination of PC(34:3) and histidine in 
the serum of patients and controls of both cohorts, and 
also including NALFD and NASH groups. Data show 
that these metabolites were specifically increased in the 
serum of patients with PSC compared with all groups.
A summary of the metabolic profiling workflow for 
selecting the best biomarker candidates in the com-
parisons of iCCA versus HCC and iCCA versus PSC 
is presented in Fig. 7.
Discussion
The liver is essential in a large variety of meta-
bolic processes that are critical for the maintenance 
of body homeostasis. Therefore, it seems reasonable 
to hypothesize that damage to this organ may have a 
reflection in serum, in terms of an imbalance in cir-
culating metabolites due to the leakage of compounds 
FIg. 7. Metabolic profiling workflow. (A) Metabolite extraction was accomplished by fractionating samples into pools of species 
with similar physicochemical properties using appropriate combinations of organic solvents, after the addition of an internal standard. 
(B) Three separate UHPLC-MS–based platforms were used to perform optimal profiling of UPLC-MS of the serum metabolome. 
(C) Data preprocessing generated a list of chromatographic peak areas for the metabolites detected in each sample injection. An 
approximated linear detection range was defined for each identified metabolite. Intra- and inter-batch normalization was carried out 
with internal standard correction and quality control calibration. (D) Once normalized, multivariate and univariate data analyses 
were performed. (E) Selection of the best candidate biomarkers for the differential diagnosis of HCC, iCCA, and PSC. The asterisks 
indicate combination of metabolites. Abbreviation: QC, quality control.
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from injured cells and/or from cancer cells with 
altered metabolic activities. The heterogeneity among 
each type of cancer cell, and the fact that tumors can 
develop in livers with different underlying diseases, 
complicates the identification of accurate serum bio-
markers. The analysis of nonspecific biomarkers, such 
as CA 19-9, may help in the noninvasive diagnosis of 
CCA. However, its specificity is low, because this bio-
marker is also elevated in one third of patients with 
PSC without biliary cancer, and in other liver diseases 
and tumors; in addition, there is an important het-
erogeneity in its elevation in patients with iCCA.(16) 
Moreover, the sensitivity of this cancer biomarker is 
compromised by the fact that ~10% of the population 
does not produce CA 19-9.(17) On the other hand, 
AFP provides low diagnostic capacity for HCC and is 
therefore not recommended for screening or diagnosis 
in Western guidelines.(18,19)
The identification of accurate noninvasive biomark-
ers remains a challenge. To date, few analyses based 
on metabolomics have been carried out in plasma/
serum for the identification of biomarkers for liver 
diseases, including cancers and PSC.(20,21) The value 
of metabolomics, and particularly lipidomics, has been 
previously highlighted in the discovery of biomark-
ers for the diagnosis of NAFLD and NASH,(13,22,23) 
which are currently in clinical use. This technique 
allowed different metabolomics subtypes of NASH 
to be identified in animal models and patients.(24) 
Moreover, integration of genomics, transcriptomics, 
and metabolomics in tumor tissue has been proposed 
for the identification of molecular subtypes of HCC 
and iCCA with similar prognosis.(25) Our metabolo-
mic study was conducted on serum searching for bio-
markers that can differentially diagnose iCCA from 
HCC, the most frequent type of liver cancer, as well 
as for PSC, a condition with an enhanced risk of 
developing iCCA. Moreover, it is important to high-
light that in this study the diagnosis of all liver tumors 
(iCCA or HCC) was biopsy-proven, and the serum 
samples had been obtained just after diagnosis and no 
treatment had been previously applied.
Among the metabolites that allowed to discrim-
inate both types of cancer, some were amino acids 
with lower levels in HCC. In this line, reductions of 
serum phenylalanine, aspartate, glutamate, glycine, 
and serine levels were reported in the progression of 
hepatitis B to HCC.(26) Also, aberrant lipid metabo-
lism has been described in patients with HCC and 
other chronic liver diseases.(21) In agreement with 
this study, we found lower levels of sphingomyelins 
in the serum from patients with HCC, and, inter-
estingly, these molecules were not altered in patients 
with iCCA. We also found increased serum levels of 
bile acids in patients with liver tumors, although these 
changes also occur in other liver diseases accompa-
nied by cholestasis, including NAFLD/NASH, and 
thus these molecules alone cannot be considered 
good biomarkers. Interestingly, the combination of 
two amino acids and two sphingomyelins permitted 
to discriminate patients with iCCA and HCC with 
an AUC of 0.890 and 0.720 in the discovery and 
validation cohorts, respectively, and other diagnostic 
models, especially the mode obtained with six metab-
olites, provided high values in both cohorts of patients 
(AUC of 0.900 and 0.929 in the discovery and valida-
tion cohorts, respectively). It is important to note that 
these diagnostic models maintained their specificity 
compared with other liver diseases such as NAFLD 
or NASH. Thus, the analysis of serum metabolites by 
UHPLC may allow the specific noninvasive diagnosis 
of both types of liver tumors, avoiding the inherent 
risks of tumor biopsy.
The diagnosis of PSC is difficult without the use 
of endoscopic retrograde cholangiopancreatogra-
phy or magnetic resonance cholangiopancreatogra-
phy techniques. Increased levels of circulating bile 
acids are a characteristic of PSC, as well as of other 
cholestatic disorders, as a result of compensatory 
mechanisms triggered by the intrahepatic accumu-
lation of bile acids.(27) The accumulation of some 
bile acid species may induce cytotoxic effects and 
act as cocarcinogenic factors promoting bile duct 
proliferation/inflammation and reducing chemopro-
tection.(28) Previous studies have described differen-
tially altered profiles of serum metabolites in PSC 
and primary biliary cirrhosis.(29,30) Here, we found 
elevated levels of primary bile acids in PSC com-
pared with iCCA. However, obstructive cholesta-
sis may occur depending on the localization of 
tumors, and high serum levels of bile acids can be 
found in some patients with iCCA.(31) Interestingly, 
increased levels of cholesterol and 38 glycerophos-
pholipids, mainly phosphatidylcholines and lyso-
phosphatidylcholines, in the serum of patients with 
PSC were found to be unaltered in patients with 
iCCA. Phosphatidylcholine species are import-
ant components of bile, playing a key role in the 
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formation of mixed micelles of bile acids and cho-
lesterol, and protecting cholangiocytes from the 
harmful detergent properties of bile acids. Reduced 
levels of phosphatidylcholines have been found in 
bile of patients with PSC and in patients with PSC-
related CCA.(32) Here, we also found a reduction of 
the essential fatty acid linoleate (18:2n6), which was 
previously reported to be elevated in the serum of 
patients with PSC, in addition to other free fatty 
acids.(30) Interestingly, in our study, the combination 
of one amino acid and one phosphatidylcholine per-
mitted to accurately differentiate between patients 
with PSC and iCCA with AUCs of 0.990 and 0.995 
in the discovery and validation cohorts, respectively.
In conclusion, serum metabolomic profiling is a 
promising noninvasive approach for the diagnosis of 
iCCA, HCC, and PSC and to distinguish patients 
with iCCA from those with HCC, as well as from 
PSC. Larger-scale validation studies in patients 
with different conditions and ethnicities are needed 
to determine the clinical diagnostic value of such 
biomarkers.
ReFeReNCeS
 1) Banales JM, Cardinale V, Carpino G, Marzioni M, 
Andersen JB, Invernizzi P, et al. Expert consensus document: 
Cholangiocarcinoma: current knowledge and future perspectives 
consensus statement from the European Network for the Study 
of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol 
Hepatol 2016;13:261-280.
 2) DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, 
Winter JM, Lillemoe KD, et al. Cholangiocarcinoma: thirty-
one-year experience with 564 patients at a single institution. Ann 
Surg 2007;245:755-762.
 3) Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia 
C. A comparison of trends in mortality from primary liver can-
cer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol 
2013;24:1667-1674.
 4) Macias RI. Cholangiocarcinoma: Biology, clinical management, 
and pharmacological perspectives. ISRN Hepatol 2014;2014: 
828074.
 5) Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet 
2014;383:2168-2179.
 6) Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel 
T, et al. Guidelines for the diagnosis and management of intra-
hepatic cholangiocarcinoma. J Hepatol 2014;60:1268-1289.
 7) Rizvi S, Eaton JE, Gores GJ. Primary sclerosing cholangitis as a 
premalignant biliary tract disease: surveillance and management. 
Clin Gastroenterol Hepatol 2015;13:2152-2165.
 8) Hensley CT, Faubert B, Yuan Q , Lev-Cohain N, Jin E, Kim 
J, et al. Metabolic heterogeneity in human lung tumors. Cell 
2016;164:681-694.
 9) Miolo G, Muraro E, Caruso D, Crivellari D, Ash A, Scalone S, 
et al. Pharmacometabolomics study identifies circulating sper-
midine and tryptophan as potential biomarkers associated with 
the complete pathological response to trastuzumab-paclitaxel 
neoadjuvant therapy in HER-2 positive breast cancer. Oncotarget 
2016;7:39809-39822.
 10) Edge SB, Compton CC. The American Joint Committee on 
Cancer: the 7th edition of the AJCC cancer staging manual and 
the future of TNM. Ann Surg Oncol 2010;17:1471-1474.
 11) Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 
2012;379:1245-1255.
 12) EASL Clinical Practice Guidelines. management of cholestatic 
liver diseases. J Hepatol 2009;51:237-267.
 13) Barr J, Caballeria J, Martinez-Arranz I, Dominguez-Diez A, 
Alonso C, Muntane J, et al. Obesity-dependent metabolic signa-
tures associated with nonalcoholic fatty liver disease progression. 
J Proteome Res 2012;11:2521-2532.
 14) Martinez-Arranz I, Mayo R, Perez-Cormenzana M, Minchole 
I, Salazar L, Alonso C, et al. Enhancing metabolomics research 
through data mining. J Proteomics 2015;127:275-288.
 15) Saccenti E, Hoefsloot HCJ, Smilde AK, Westerhuis JA, 
Hendriks MMWB. Reflections of univariate and multivariate 
analysis of metabolomics data. Metabolomics 2014;10:361-374.
 16) Macias RIR, Banales JM, Sangro B, Muntane J, Avila MA, 
Lozano E, et al. The search for novel diagnostic and prognostic 
biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol 
Basis Dis 2018;1864:1468-1477.
 17) Liang B, Zhong L, He Q , Wang S, Pan Z, Wang T, et al. 
Diagnostic accuracy of serum CA19-9 in patients with cholan-
giocarcinoma: a systematic review and meta-analysis. Med Sci 
Monit 2015;21:3555-3563.
 18) Kelly SL, Bird TG. The evolution of the use of serum alpha- 
fetoprotein in clinical liver cancer surveillance. J Immunobiol 
2016;1.
 19) European Association For The Study Of The Liver; European 
Organisation For Research And Treatment Of Cancer. EASL-
EORTC clinical practice guidelines: management of hepatocel-
lular carcinoma. J Hepatol 2012;56:908-943.
 20) Wang B, Chen D, Chen Y, Hu Z, Cao M, Xie Q , et al. 
Metabonomic profiles discriminate hepatocellular carcinoma 
from liver cirrhosis by ultraperformance liquid chromatogra-
phy-mass spectrometry. J Proteome Res 2012;11:1217-1227.
 21) Chen S, Yin P, Zhao X, Xing W, Hu C, Zhou L, et al. Serum 
lipid profiling of patients with chronic hepatitis B, cirrhosis, 
and hepatocellular carcinoma by ultra fast LC/IT-TOF MS. 
Electrophoresis 2013;34:2848-2856.
 22) Barr J, Vazquez-Chantada M, Alonso C, Perez-Cormenzana 
M, Mayo R, Galan A, et al. Liquid chromatography-mass spec-
trometry-based parallel metabolic profiling of human and mouse 
model serum reveals putative biomarkers associated with the 
progression of nonalcoholic fatty liver disease. J Proteome Res 
2010;9:4501-4512.
 23) Mayo R, Crespo J, Marinez-arranz I, Banales JM, Arias M, 
Minchole I, et al. Metabolomic-based noninvasive serum test to 
diagnose nonalcoholic steatohepatitis: Results from discovery 
and validation cohorts. Hepatol Commun 2018;2:807-820.
 24) alonso C, Fernandez-Ramos D, Varela-Rey M, Martinez-
Arranz I, Navasa N, Van Liempd SM, et al. Metabolomic 
identification of subtypes of nonalcoholic steatohepatitis. 
Gastroenterology 2017;152:1449-1461.e1447.
 25) Chaisaingmongkol J, Budhu a, Dang H, Rabibhadana S, 
Pupacdi B, Kwon SM, et al. Common molecular subtypes among 
Asian hepatocellular carcinoma and cholangiocarcinoma. Cancer 
Cell 2017;32:57-70.e53.
 26) Gao R, Cheng J, Fan C, Shi X, Cao Y, Sun B, et al. Serum me-
tabolomics to identify the liver disease-specific biomarkers for 
the progression of hepatitis to hepatocellular carcinoma. Sci Rep 
2015;5:18175.
Hepatology, august 2019BANALES, ET AL.
562
 27) Marin JJ, Macias RI, Briz O, Banales JM, Monte MJ. Bile acids 
in physiology, pathology and pharmacology. Curr Drug Metab 
2015;17:4-29.
 28) Lozano E, Sanchez-Vicente L, Monte MJ, Herraez E, Briz O, 
Banales JM, et al. Cocarcinogenic effects of intrahepatic bile acid 
accumulation in cholangiocarcinoma development. Mol Cancer 
Res 2014;12:91-100.
 29) Trottier J, Bialek A, Caron P, Straka RJ, Heathcote J, 
Milkiewicz P, et al. Metabolomic profiling of 17 bile acids in 
serum from patients with primary biliary cirrhosis and primary 
sclerosing cholangitis: a pilot study. Dig Liver Dis 2012;44: 
303-310.
 30) Bell LN, Wulff J, Comerford M, Vuppalanchi R, Chalasani 
N. Serum metabolic signatures of primary biliary cirrho-
sis and primary sclerosing cholangitis. Liver Int 2015;35: 
263-274.
 31) Sombattheera S, Proungvitaya T, Limpaiboon T, Wongkham S, 
Wongkham C, Luvira V, et al. Total serum bile acid as a po-
tential marker for the diagnosis of cholangiocarcinoma without 
jaundice. Asian Pac J Cancer Prev 2015;16:1367-1370.
 32) Gauss A, Ehehalt R, Lehmann WD, Erben G, Weiss KH, 
Schaefer Y, et al. Biliary phosphatidylcholine and lysophos-
phatidylcholine profiles in sclerosing cholangitis. World  
J Gastroenterol 2013;19:5454-5463.
Author names in bold designate shared co-first authorship.
Supporting Information
Additional Supporting Information may be found at 
onlinelibrary.wiley.com/doi/10.1002/hep.30319/suppinfo. 
